NO Kravchun¹*, IP Dunaieva², IA Ilchenko², PP Kravchun³ and IV Cherniavskaia⁴

¹Multidisciplinary Medical Center “Life Park”, Kharkiv, Ukraine ²Kharkiv National Medical University of the Ministry of Health of Ukraine, Kharkiv, Ukraine ³IQVIA RDS, Kyiv, Ukraine ⁴Medical Center “REFIT”, Kharkiv, Ukraine

*Corresponding Author: NO Kravchun, Multidisciplinary Medical Center “Life Park”, Kharkiv, Ukraine.

Received: October 07, 2021; Published: November 23, 2021

Abstract

The article evaluates the structural and functional changes of the myocardium in patients with postinfarction cardiosclerosis, hypertension and type 2 diabetes depending on the systolic function of the left ventricle and the functional class of chronic heart failure. A study of 68 patients with postinfarction cardiosclerosis, hypertension and type 2 diabetes mellitus was performed. The comparison group included 60 patients with postinfarction cardiosclerosis, the control group - 30 almost healthy individuals. Type 2 diabetes mellitus is a potentiator of left ventricular myocardial remodeling in patients with systolic dysfunction caused by postinfarction cardiosclerosis. Comorbidity of postinfarction cardiosclerosis, arterial hypertension and type 2 diabetes mellitus leads to the progression of postinfarction remodeling.

Keywords: Postinfarction Cardiosclerosis; Type 2 Diabetes Mellitus; Chronic Heart Failure; Systolic Dysfunction

References

1. V Ormazabal., et al. “Association between insulin resistance and the development of cardiovascular disease”. Cardiovascular Diabetology 17 (2018): 122.
2. Petrie JR., et al. “Diabetes, Hypertension, and cardiovascular disease: Clinical Insights and Vascular Mechanisms”. Canadian Journal of Cardiology 5 (2018): 575-584.
3. Zhou MS., et al. “Link between the renin-angiotensin system and insulin resistance: implications for cardiovascular disease”. Vascular Medicine 5 (2012): 330-341.
4. B Williams., et al. “ESC/ESH Guidelines for the management of arterial hypertension”. European Heart Journal 33 (2018): 3021-3104.
5. Serhiyenko V and Serhiyenko O. “Diabetes mellitus and arterial hypertension”. International journal of endocrinology (Ukraine) 2 (2021): 175-188.
6. G Lastra., et al. “Type 2 diabetes mellitus and hypertension: an update”. Endocrinology and Metabolism Clinics of North America 1 (2014): 103-122.
7. Savoia C and Touyz RM. “Hypertension, Diabetes Mellitus, and Excess Cardiovascular Risk: Importance of Baseline Systolic Blood Pressure”. Hypertension5 (2017): 882-883.
8. Gorbunova O., et al. “The level of protection from oxidative stress and three-year dynamics of structural and functional changes of the myocardium in chronic ischemic heart disease in men”. Georgian Medical News 285 (2018): 63-69.
9. M Fudim., et al. “The Prognostic Value of Diastolic and Systolic Mechanical Left Ventricular Dyssynchrony Among Patients with Coronary Heart Disease”. JACC Cardiovascular Imaging7 (2019): 1215-1226.
10. Y Lin., et al. “Effect of Trimetazidine on Diabetic Patients with Coronary Heart Diseases: A Meta-Analysis of Randomized, Controlled Trials”. Chinese Medical Sciences Journal3 (2020): 226-238.
11. Chen Y., et al. “Blood glucose fluctuations in patients with coronary heart disease and diabetes mellitus correlates with heart rate variability: A retrospective analysis of 210 cases”. Nigerian Journal of Clinical Practice9 (2020): 1194-1200.
12. SJ Shah., et al. “Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF”. European Heart Journal37 (2018): 3439-3450.
13. Zhou D., et al. “Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: the NHANES III Linked Mortality Study”. Scientific Reports1 (2018): 9418.
14. Frangogiannis NG and Kovacic JC. “Extracellular Matrix in Ischemic Heart Disease, Part 4/4: JACC Focus Seminar”. Journal of the American College of Cardiology17 (2020): 2219-2235.
15. Verbovoy AF., et al. “Diabetic macroangiopathy”. Therapeutic archive 10 (2019): 139-143.
16. AF Verbovoy., et al. “Modern approaches to management of cardiovascular risk factors at patients with diabetes mellitus type 2”. Therapeutic archive 8 (2018): 113-117.
17. NR Poulter., et al. “Are the American Heart Association/American College of Cardiology High Blood Pressure Guidelines Fit for Global Purpose? Thoughts From the International Society of Hypertension”. Hypertension2 (2018): 260-262.
18. B Williams., et al. “2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension”. Journal of Hypertension33 (2018): 3021-3104.
19. T Unger., et al. “2020 International Society of Hypertension Global Hypertension Practice Guidelines”. Hypertension6 (2020): 1334-1357.
20. Green JB. “Understanding the type 2 diabetes mellitus and cardiovascular disease risk paradox”. Postgraduate Medical3 (2014): 190-204.
21. M Guglin., et al. “Heart failure as a risk factor for diabetes mellitus”. Cardiology2 (2014): 84-92.
22. H Ohuchi., et al. “Low fasting plasma glucose level predicts morbidity and mortality in symptomatic adults with congenital heart disease”. International Journal of Cardiology2 (2014): 306-312.
23. C Varas-Lorenzo., et al. “The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and metaanalysis of published observational studies”. BMC Cardiovascular Disorders1 (2014): 129.

Citation

Citation: NO Kravchun., et al. “Structural and Functional Changes of Myocardium Under Conditions of Postinfarcate Cardiosclerosis, Arterial Hypertension, Type 2 Diabetes Mellitus". Acta Scientific Gastrointestinal Disorders 4.12 (2021): 42-46.

Copyright

Copyright: © 2021 NO Kravchun., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.